99 related articles for article (PubMed ID: 16711753)
41. C-type lectin Mermaid inhibits dendritic cell mediated HIV-1 transmission to CD4+ T cells.
Nabatov AA; de Jong MA; de Witte L; Bulgheresi S; Geijtenbeek TB
Virology; 2008 Sep; 378(2):323-8. PubMed ID: 18597806
[TBL] [Abstract][Full Text] [Related]
42. [Anti-HIV-1 effect of compound K3 from flower of Japanese pagoda tree in vitro].
Zhang GH; Zheng YT
Zhong Yao Cai; 2006 Apr; 29(4):355-8. PubMed ID: 16913492
[TBL] [Abstract][Full Text] [Related]
43. [ADS-J1 antagonizes semen-derived enhancer of virus infection-mediated enhancement of transmitted founder HIV-1 and its matched chronic control strain infection].
Liu HM; Ma NN; Luo C; Yuan SY; Liu FL; Yao XG; Zhou CQ; Zou M
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Feb; 38(2):211-216. PubMed ID: 29502062
[TBL] [Abstract][Full Text] [Related]
44. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.
Clayton R; Ohagen A; Nicol F; Del Vecchio AM; Jonckers TH; Goethals O; Van Loock M; Michiels L; Grigsby J; Xu Z; Zhang YP; Gutshall LL; Cunningham M; Jiang H; Bola S; Sarisky RT; Hertogs K
Antiviral Res; 2009 Nov; 84(2):142-9. PubMed ID: 19699239
[TBL] [Abstract][Full Text] [Related]
45. Interaction of HIV-1 with dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-expressing cells is influenced by gp120 envelope modifications associated with disease progression.
Nabatov AA; van Montfort T; Geijtenbeek TB; Pollakis G; Paxton WA
FEBS J; 2006 Nov; 273(21):4944-58. PubMed ID: 17010165
[TBL] [Abstract][Full Text] [Related]
46. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
[TBL] [Abstract][Full Text] [Related]
47. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development.
Kadow J; Wang HG; Lin PF
Curr Opin Investig Drugs; 2006 Aug; 7(8):721-6. PubMed ID: 16955683
[TBL] [Abstract][Full Text] [Related]
48. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
49. Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?
Herbeuval JP; Shearer GM
AIDS Rev; 2006; 8(1):3-8. PubMed ID: 16736946
[TBL] [Abstract][Full Text] [Related]
50. Computational study of HIV gp120 as a target for polyanionic entry inhibitors: Exploiting the V3 loop region.
Hollingsworth LR; Brown AM; Gandour RD; Bevan DR
PLoS One; 2018; 13(1):e0190658. PubMed ID: 29346393
[TBL] [Abstract][Full Text] [Related]
51. Benzopurpurin and related compounds inhibit the binding of gp120 to galactosyl ceramide/sulfatide and infection of human immunodeficiency virus.
Bhat S; Otsuka T; Srinivasan A
DNA Cell Biol; 1994 Feb; 13(2):211-6. PubMed ID: 8179824
[TBL] [Abstract][Full Text] [Related]
52. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy.
Williamson MP; McCormick TG; Nance CL; Shearer WT
J Allergy Clin Immunol; 2006 Dec; 118(6):1369-74. PubMed ID: 17157668
[TBL] [Abstract][Full Text] [Related]
53. Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase.
Du L; Zhao YX; Yang LM; Zheng YT; Tang Y; Shen X; Jiang HL
Acta Pharmacol Sin; 2008 Oct; 29(10):1261-7. PubMed ID: 18817633
[TBL] [Abstract][Full Text] [Related]
54. Blocking HIV-1 entry by a gp120 surface binding inhibitor.
Tsou LK; Chen CH; Dutschman GE; Cheng YC; Hamilton AD
Bioorg Med Chem Lett; 2012 May; 22(9):3358-61. PubMed ID: 22487177
[TBL] [Abstract][Full Text] [Related]
55. ADS-J1 disaggregates semen-derived amyloid fibrils.
Li J; Yang Z; Liu H; Qiu M; Zhang T; Li W; Li Z; Qi T; Qiu Y; Li L; Zhou X; Liu S; Tan S
Biochem J; 2019 Mar; 476(6):1021-1035. PubMed ID: 30877194
[TBL] [Abstract][Full Text] [Related]
56. [Naphthalenedisulfonic acid (NDS) derivatives as anti-HIV agents].
Baba M; Shigeta S
Nihon Rinsho; 1993 Sep; 51 Suppl():153-7. PubMed ID: 8271379
[No Abstract] [Full Text] [Related]
57. Inhibition of certain strains of HIV-1 by cell surface polyanions in the form of cholesterol-labeled oligonucleotides.
Ahn KS; Ou W; Silver J
Virology; 2004 Dec; 330(1):50-61. PubMed ID: 15527833
[TBL] [Abstract][Full Text] [Related]
58. Tetra-end-linked oligonucleotides forming DNA G-quadruplexes: a new class of aptamers showing anti-HIV activity.
Oliviero G; Amato J; Borbone N; D'Errico S; Galeone A; Mayol L; Haider S; Olubiyi O; Hoorelbeke B; Balzarini J; Piccialli G
Chem Commun (Camb); 2010 Dec; 46(47):8971-3. PubMed ID: 20972507
[TBL] [Abstract][Full Text] [Related]
59. Sulfated polysaccharides (chondroitin sulfate and carrageenan) plus glucosamine sulfate are potent inhibitors of HIV.
Konlee M
Posit Health News; 1998; (No 17):4-7. PubMed ID: 11366556
[TBL] [Abstract][Full Text] [Related]
60. Application of deep learning and molecular modeling to identify small drug-like compounds as potential HIV-1 entry inhibitors.
Andrianov AM; Nikolaev GI; Shuldov NA; Bosko IP; Anischenko AI; Tuzikov AV
J Biomol Struct Dyn; 2022 Oct; 40(16):7555-7573. PubMed ID: 33855929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
